Showing results (111-120 of 179) with videos related to

Sort By:
Pageof 18
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2020
Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal AdenocarcinomaSamuel O Antwi, William R Bamlet, Richard M Cawthon, et al.
JCO Oncology Practice|May 26, 2022
Economic Cost and Sustainability of Oral Therapies in Precision OncologyAakash P Desai, Caleb J Scheckel, Leah C Soderberg, et al.
Plos One|September 19, 2019
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptomsEdward Wolin, Alain Mita, Amit Mahipal, et al.
Annals of Surgical Oncology|August 16, 2022
Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot StudyTravis E Grotz, Jennifer A Yonkus, Cornelius A Thiels, et al.
Surgery|August 21, 2023
Differences in the surgical management of early-stage hepatocellular carcinoma at minority versus non-minority-serving hospitalsMohamedraed Elshami, Lauryn Bailey, Richard S Hoehn, et al.
Cancers|April 3, 2021
Aspirin and Statin Use and the Risk of Gallbladder CancerKritika Prasai, Sri Harsha Tella, Siddhartha Yadav, et al.
JCO Precision Oncology|June 30, 2022
Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract CancerSavannah S Liddell, Sakti Chakrabarti, Grant A Wintheiser, et al.
Research Square|May 15, 2024
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid TumorsMahesh Seetharam, Aurora Norman, Jacob Allred, et al.
Annals of Surgical Oncology|June 27, 2023
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic CholangiocarcinomaShishir K Maithel, Jessica M Keilson, Hop S Tran Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid TumorsAndrew J Wagner, Udai Banerji, Amit Mahipal, et al.
Pageof 18